Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ustekinumab in moderate to severe plaque psoriasis (PHOENIX 1)
NCT00267969Phase 3Completed
- Sponsor
- Johnson & Johnson
- Start
- Dec 2005
- Primary completion
- Jul 2006
- Modality
- Monoclonal Antibodies
- Countries
- 3
01
Overview
A Phase 3 trial of ustekinumab in plaque psoriasis, sponsored by Johnson & Johnson. Started Dec 2005; status: completed.
02
Drugs
ustekinumab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT00267969.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00267969.